Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002856 | 0.78 | GHSR (0.69) | HRH4POLBMEN1KMT2AGHSR | |
| SCHEMBL3039407 | 0.74 | MAPK14 (0.64) | HRH4MEN1KMT2AGHSRHPGD | |
| SCHEMBL3545296 | 0.74 | AURKA (0.55) | KMT2AHPGD | |
| SCHEMBL15230252 | 0.72 | POLB (0.48) | HRH4HRH3POLBMEN1KMT2A | |
| SCHEMBL994974 | 0.72 | RHEB (0.44) | BRD4MEN1KMT2AHPGDTSHR | |
| SCHEMBL3546474 | 0.72 | NPC1 (0.45) | POLBMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL26111372 | 0.72 | RHEB (0.41) | BRD4HPGD | |
| SCHEMBL18387753 | 0.72 | RHEB (0.41) | BRD4KMT2ALMNAHPGD | |
| SCHEMBL29507057 | 0.72 | NPC1 (0.45) | POLBMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL2379228 | 0.72 | HPGD (0.77) | POLBMEN1KMT2ALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662824-B2 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662824-B2 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662824-B2 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006101937-A1 | ACYLHYDRAZONES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066610-A1 | Acylhydrazones as kinase modulators | MET, ERBB2, ERBB3 | HRH4 1092/4885HRH3 1343/4885POLB 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.